EUVIMEDEUVIMED felfedezése
Crossref

Adjuvant and salvage radiotherapy after neoadjuvant therapy and radical prostatectomy for high‐risk localized prostate cancer

Praful Ravi iD, Lucia Kwak, Wout Devlies, Wanling Xie, Fallon Chipidza, Xiaoyu Yang, Glenn Bubley, Irving Kaplan, Adam S Kibel iD, Paul Nguyen, Mary-Ellen Taplin

The Prostate · 2024

DOI: 10.1002/pros.24653 ↗

At a glance

Journal article in The Prostate, 2024. Written by Praful Ravi and 10 co-authors. Institution: Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA. Major MEDLINE topics: Prostate-Specific Antigen, Prostatic Neoplasms. Cited 3 times so far (Crossref); 26 references. Funded by: Janssen Pharmaceutics, Medivation/Astellas, GSK, and AstraZeneca.

AbsztraktSubjectsBibliográfiai adatokCiteRelated studies

Abstract (original language)

Background

We sought to describe patterns of delivery of adjuvant (aRT) and salvage RT (sRT) in patients who underwent RP after receiving neoadjuvant androgen receptor pathway inhibitor (ARPI) before radical prostatectomy (RP) for high‐risk localized prostate cancer (HRLPC).

Methods

Two hundred eighteen patients treated on phase 2 neoadjuvant trials between 2006 and 2018 at two academic centers were evaluated. aRT and sRT were defined as receipt of RT with a PSA of ≤0.1 or >0.1 ng/mL, respectively. Primary outcomes were biochemical recurrence (BCR), defined as time from aRT/sRT to a PSA rising to >0.1 ng/mL, and metastasis‐free survival (MFS) after RT.

Results

Twenty‐three (11%) and 55 (25%) patients received aRT and sRT respectively. Median PSA at start of aRT and sRT was 0.01 and 0.16 ng/mL, and median duration from RP to RT was 5 and 14 months, respectively. All aRT patients had NCCN high‐risk disease, 30% were pN1 and 43% had positive surgical margins; 52% had prostate bed RT. Fifty‐one percent of sRT patients had biopsy Gleason 9–10, 29% were pT2 and 9% had positive surgical margins; 63% had RT to the prostate bed/pelvis. At a median follow‐up of 5.3 and 3.0 years after aRT and sRT, 3‐year freedom from BCR was 55% and 47%, and 3‐year MFS was 56% and 53%, respectively. Conclusions aRT was infrequently used in patients who received neoadjuvant ARPI before RP for HRLPC. Outcomes of aRT and sRT were similar but generally poor. Studies evaluating intensified systemic therapy approaches with postoperative RT in this high‐risk population are needed.

Subjects

MeSH terms (MEDLINE)

Prostate-Specific AntigenProstatic NeoplasmsMaleHumansProstateNeoadjuvant TherapyRadiotherapy, AdjuvantMargins of ExcisionProstatectomyAdjuvants, PharmaceuticSalvage TherapyNeoplasm Recurrence, LocalRetrospective Studies

Author keywords

adjuvant radiotherapybiochemical recurrencehigh-risk prostate cancermetastasis-free survivalneoadjuvantsalvage radiotherapy

Substances

Prostate-Specific AntigenAdjuvants, Pharmaceutic

Authors and institutions

  • Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Department of Urology, KU Leuven, Leuven, Belgium.
  • Department of Radiation Oncology, Brigham & Women's Hospital, Boston, Massachusetts, USA.
  • Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
  • Department of Urology, Brigham & Women's Hospital, Boston, Massachusetts, USA.

ORCID profiles: Praful Ravi, Adam S Kibel

Funding

  • Janssen Pharmaceutics, Medivation/Astellas, GSK, and AstraZeneca

Cite

APA

Ravi, P., Kwak, L., Devlies, W., Xie, W., Chipidza, F., Yang, X., Bubley, G., Kaplan, I., Kibel, A. S., Nguyen, P., & Taplin, M. E. (2024). Adjuvant and salvage radiotherapy after neoadjuvant therapy and radical prostatectomy for high‐risk localized prostate cancer. The Prostate. https://doi.org/10.1002/pros.24653

Vancouver

Ravi P, Kwak L, Devlies W, Xie W, Chipidza F, Yang X, et al. Adjuvant and salvage radiotherapy after neoadjuvant therapy and radical prostatectomy for high‐risk localized prostate cancer. The Prostate. 2024. doi:10.1002/pros.24653

BibTeX
@article{Ravi2024,
  author = {Ravi, Praful and Kwak, Lucia and Devlies, Wout and Xie, Wanling and Chipidza, Fallon and Yang, Xiaoyu and Bubley, Glenn and Kaplan, Irving and Kibel, Adam S and Nguyen, Paul and Taplin, Mary-Ellen},
  title = {Adjuvant and salvage radiotherapy after neoadjuvant therapy and radical prostatectomy for high‐risk localized prostate cancer},
  journal = {The Prostate},
  year = {2024},
  doi = {10.1002/pros.24653}
}
Start for free →